JPH06508515A - トランスジェニック哺乳類の乳汁中への所望なタンパク質の産生 - Google Patents
トランスジェニック哺乳類の乳汁中への所望なタンパク質の産生Info
- Publication number
- JPH06508515A JPH06508515A JP4511080A JP51108092A JPH06508515A JP H06508515 A JPH06508515 A JP H06508515A JP 4511080 A JP4511080 A JP 4511080A JP 51108092 A JP51108092 A JP 51108092A JP H06508515 A JPH06508515 A JP H06508515A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sequence
- wap
- milk
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 103
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 73
- 210000004080 milk Anatomy 0.000 title claims abstract description 49
- 235000013336 milk Nutrition 0.000 title claims abstract description 48
- 239000008267 milk Substances 0.000 title claims abstract description 48
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 22
- 241000124008 Mammalia Species 0.000 title claims description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 238000000034 method Methods 0.000 claims abstract description 48
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 41
- 241001465754 Metazoa Species 0.000 claims abstract description 33
- 101710087237 Whey acidic protein Proteins 0.000 claims abstract description 33
- 239000012634 fragment Substances 0.000 claims abstract description 22
- 230000014509 gene expression Effects 0.000 claims abstract description 20
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 13
- 210000005075 mammary gland Anatomy 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 6
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 4
- 108010054218 Factor VIII Proteins 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000003999 initiator Substances 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 3
- 108090000394 Erythropoietin Proteins 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 229940105423 erythropoietin Drugs 0.000 claims description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 3
- 229960005356 urokinase Drugs 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 2
- 239000000854 Human Growth Hormone Substances 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000002753 trypsin inhibitor Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000013365 dairy product Nutrition 0.000 claims 1
- 108010034251 factor VIII delta II Proteins 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 47
- 101150059663 WAP gene Proteins 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 9
- 238000011830 transgenic mouse model Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 108010006025 bovine growth hormone Proteins 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 102100024819 Prolactin Human genes 0.000 description 5
- 108010057464 Prolactin Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000122 growth hormone Substances 0.000 description 5
- 229940097325 prolactin Drugs 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 101150055766 cat gene Proteins 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 3
- 102000008192 Lactoglobulins Human genes 0.000 description 3
- 108010060630 Lactoglobulins Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 101000854964 Mus musculus Whey acidic protein Proteins 0.000 description 2
- 101000947125 Rattus norvegicus Beta-casein Proteins 0.000 description 2
- 101000667278 Rattus norvegicus Whey acidic protein Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 102000051631 human SERPINA1 Human genes 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000001983 lactogenic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 101100373020 Mus musculus Wap gene Proteins 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101100317259 Rattus norvegicus Wap gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 101150067977 ap gene Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008176 mammary development Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Dairy Products (AREA)
Abstract
Description
Claims (20)
- 1.雌哺乳動物の乳汁中への成熟した形態または融合した形態での目的の異種タ ンパク質の製造法であって、前記雌哺乳動物を飼育し、 乳汁を回収して、そこから前記タンパク質を回収して必要ならば単離することを 含んでなり、前記雌哺乳動物は、そのゲノム中に、ウサギWAPタンパク質を発 現させる要素中に存在しかつ完全なWAPプロモータの3′末端かせ少なくとも 3Kbの長さを有するフラグメント上に位置している少なくとも一つの配列の制 御下にある、目的のタンパク質をコードする配列が組み込まれてなるトランスジ ェニック動物であることを特徴とする方法に関する。
- 2.前記目的の異種タンパク質をコードする配列が、完全なウサギWAPプロモ ーターの3′末端から3Kbと6.3Kbとの間のフラグメント上に位置してい る少なくとも一つの発現要素を更に含んでなる配列によって制御されている、請 求の範囲第1項に記載の方法。
- 3.前記の異種タンパク質をコードする配列が、完全なウサギWAPプロモータ ーの3′末端から6.3Kbの長さのフラグメント上に配置された総ての発現要 素を含む配列によって制御されている、請求の範囲第1項または第2項に記載の 方法。
- 4.WAPプロモーターの配列が、第1図に示されるHindIIIとBamH I部位の間の6.3Kb配列に位置するた発現要素を含むものである、請求の範 囲第3項に記載の方法。
- 5.前記目的の異種タンパク質をコードする配列が、完全なウサギWAPプロモ ーターの3′末端から17Kbの長さのフラグメント上に位置している総ての発 現要素を含む配列の制御下にある、請求の範囲第1〜4項のいずれか一項に記載 の方法。
- 6.WAPプロモーターの配列が、第1図に示されているHindIIIとEc oRIとの間の17Kbの配列上に位置している発現要素を含むものである、請 求の範囲第5項に記載の方法。
- 7.前記目的のタンパク質をコードする配列の前の5′末端側に、ウサギWAP 遺伝子の完全プロモーターに対応する配列またはプロモーター機能を保持する同 等な配列が存在する、請求の範囲第1〜6項のいずれか一項に記載の方法。
- 8.前記目的のタンパク質の前に、全てのWAP遺伝子およびこの遺伝子のWA Pプロモーターまたは同等の配列が存在する、請求の範囲第1〜7項のいずれか 一項に記載の方法。
- 9.ウサギWAPタンパク質遺伝子に対応する配列において、イニシエーターの AUGコドンが欠失している、請求の範囲第1〜8項のいずれか1項に記載の方 法。
- 10.異種タンパク質をコードする配列に対応する配列において、イニシエータ ーのAUGコドンが欠失している、請求の範囲第1〜9項のいずれか1項に記載 の方法。
- 11.前記雌哺乳動物の乳汁から目的のタンパク質を回収するために、 a)乳腺を回収し、 b)この乳腺を、温度0℃で2時間〜18時間インキュベートし、 c)乳腺から自然に滲出した乳汁を回収し、d)この乳汁から目的のタンパク質 を単離して、前記の精製したタンパク質を得る、 請求の範囲第1〜10項のいずれか一項に記載の方法。
- 12.異種タンパク質をコードする配列が、ヒト成長ホルモンをコードする配列 である、請求の範囲第1〜11項のいずれか一項に記載の方法。
- 13.異種タンパク質が、 成長因子、 インターロイキン、 刺激因子、 キナーゼ、 凝固因子、 α−抗トリプシン、 ヒルジン から選択される、請求の範囲第1〜12項のいずれか一項に記載の方法。
- 14.タンパク質が、 エリスロポエチン G−CSF, α−抗トリプシン ウロキナーゼ、 VIII因子 から選択される、請求の範囲13項に記載の方法。
- 15.目的のタンパク質をコードする配列が、VIII因子遺伝子の最初のイン トロンの後にあるヒトVIII−ΔII因子のcDNAである、請求の範囲第1 4項に記載の方法。
- 16.請求の範囲第1〜15項のいずれか一項に記載の方法を使用して得られた 目的のタンパク質を含む乳汁または乳製品。
- 17.ゲノム中に目的の異種タンパク質をコードする配列を含み、それがウサギ WAPプロモーターまたはプロモーター機能を保持する同等の配列によって制御 されている、真核細胞。
- 18.雌哺乳動物の乳房の主要上皮細胞である、請求の範囲第17項に記載の真 核細胞。
- 19.請求の範囲第17および18項のいずれか一項に記載の細胞を含んでなる 、トランスジェニック動物。
- 20.ウサギWAPタンパク質を発現させる要素中に存在しかつ完全なWAPプ ロモーターの3′末端から少なくとも3Kbの長さを有するフラグメント上に位 置している少なくとも1個の配列の制御下にある、目的のタンパク質をコードす る少なくとも1種類の異種遺伝子を含んでなる、DNA配列。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9107179A FR2677652B1 (fr) | 1991-06-12 | 1991-06-12 | Procede de preparation d'une proteine d'interet dans le lait d'un animal transgenique, produit obtenu et cellule eucaryote utilisee. |
FR91/07179 | 1991-06-12 | ||
PCT/FR1992/000533 WO1992022644A1 (fr) | 1991-06-12 | 1992-06-12 | Production d'une proteine d'interet dans le lait d'un mammifere transgenique |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06508515A true JPH06508515A (ja) | 1994-09-29 |
JP3824632B2 JP3824632B2 (ja) | 2006-09-20 |
Family
ID=9413760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51108092A Expired - Lifetime JP3824632B2 (ja) | 1991-06-12 | 1992-06-12 | トランスジェニック哺乳類の乳汁中への所望なタンパク質の産生 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0527063B1 (ja) |
JP (1) | JP3824632B2 (ja) |
AT (1) | ATE248221T1 (ja) |
CA (1) | CA2111238C (ja) |
DE (1) | DE69233173T2 (ja) |
DK (1) | DK0527063T3 (ja) |
ES (1) | ES2206444T3 (ja) |
FR (1) | FR2677652B1 (ja) |
PT (1) | PT527063E (ja) |
WO (1) | WO1992022644A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831141A (en) * | 1991-01-11 | 1998-11-03 | United States Of America As Represented By The Department Of Health And Human Services | Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter |
EP0804070B1 (en) * | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
GB9406974D0 (en) * | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
US5627268A (en) * | 1994-06-07 | 1997-05-06 | Dnx Biotherapeutics | Hemoglobin comprising globin fusion proteins |
US5821351A (en) * | 1994-06-10 | 1998-10-13 | Dnx Biotherapeutics | Production of hemoglobin having a delta-like globin |
US6518482B2 (en) | 1994-09-13 | 2003-02-11 | American National Red Cross | Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor |
US5880327A (en) | 1994-09-21 | 1999-03-09 | American National Red Cross | Transgenic mammals expressing human coagulation factor VIII |
US5907080A (en) * | 1995-11-30 | 1999-05-25 | Nexia Biotechnologies, Inc. | Method for development of transgenic dwarf goats |
WO2001000855A1 (en) | 1999-06-23 | 2001-01-04 | Ppl Therapeutics (Scotland) Ltd. | Fusion proteins incorporating lysozyme |
EP1217071B1 (en) * | 2000-12-22 | 2010-04-28 | Institut National De La Recherche Agronomique | Position-independent and tissue specific expression of a transgene in milk of transgenic animals |
US8435940B2 (en) | 2006-01-05 | 2013-05-07 | University Of Utah Research Foundation | Methods and compositions related to improving properties of pharmacological agents targeting nervous system |
FR2901707B1 (fr) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
FR2910786B1 (fr) | 2006-12-29 | 2017-08-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) | "procede d'extraction d'une proteine presente dans du lait" |
FR2920024B1 (fr) | 2007-08-14 | 2012-12-14 | Lfb Biotechnologies | Procede de purification ou de detection d'une proteine cible |
FR2940655B1 (fr) | 2008-12-31 | 2011-02-18 | Lfb Biotechnologies | Peptides isoles de facteur vii de lapin. |
FR2942232B1 (fr) | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine de la coagulation et procedes pour sa mise en oeuvre |
FR2942231B1 (fr) | 2009-02-19 | 2015-03-20 | Lfb Biotechnologies | Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations |
FR2948665B1 (fr) | 2009-07-31 | 2011-09-23 | Lfb Biotechnologies | Procede pour la purification de proteines de la coagulation a domaine gla actives |
FR2948664B1 (fr) | 2009-07-31 | 2013-11-01 | Lfb Biotechnologies | Procede pour la purification de proteines de la coagulation a domaine gla |
FR2958496A1 (fr) | 2010-04-09 | 2011-10-14 | Bioprotein Technologies Sa | Preparation de proteine plasmatique de transfert des phospholipides (pltp) humaine recombinante a partir du lait d'animaux transgeniques. |
EP2651429B1 (en) | 2010-12-15 | 2018-03-28 | Neuroadjuvants, Inc. | Neuropeptide analogs, compositions, and methods for treating pain |
FR2983212A1 (fr) | 2011-11-28 | 2013-05-31 | Lfb Biotechnologies | Aptameres anti-fh, procede pour leur obtention et utilisations |
EP2687595B1 (en) | 2012-07-19 | 2018-05-30 | Laboratoire Français du Fractionnement et des Biotechnologies | Method for purifying transgenic factor VII |
FR3006591B1 (fr) | 2013-06-11 | 2016-05-06 | Lab Francais Du Fractionnement | Composition de facteur vii presentant un point isoelectrique substantiellement homogene |
FR3011250A1 (fr) | 2013-09-30 | 2015-04-03 | Lab Francais Du Fractionnement | Acides nucleiques se liant specifiquement au facteur ix/ixa humain, et utilisations |
FR3082427B1 (fr) | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3751873T2 (de) * | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
EP0832981A1 (en) * | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
WO1991003551A1 (en) * | 1989-09-11 | 1991-03-21 | Tsi-Mason Research Institute | Production of growth hormone in transgenic animal milk |
-
1991
- 1991-06-12 FR FR9107179A patent/FR2677652B1/fr not_active Expired - Lifetime
-
1992
- 1992-06-12 WO PCT/FR1992/000533 patent/WO1992022644A1/fr active Application Filing
- 1992-06-12 PT PT92401635T patent/PT527063E/pt unknown
- 1992-06-12 CA CA002111238A patent/CA2111238C/fr not_active Expired - Lifetime
- 1992-06-12 ES ES92401635T patent/ES2206444T3/es not_active Expired - Lifetime
- 1992-06-12 EP EP92401635A patent/EP0527063B1/fr not_active Expired - Lifetime
- 1992-06-12 DK DK92401635T patent/DK0527063T3/da active
- 1992-06-12 DE DE69233173T patent/DE69233173T2/de not_active Expired - Lifetime
- 1992-06-12 JP JP51108092A patent/JP3824632B2/ja not_active Expired - Lifetime
- 1992-06-12 AT AT92401635T patent/ATE248221T1/de active
Also Published As
Publication number | Publication date |
---|---|
JP3824632B2 (ja) | 2006-09-20 |
DE69233173T2 (de) | 2004-05-27 |
DE69233173D1 (de) | 2003-10-02 |
FR2677652B1 (fr) | 2005-05-27 |
DK0527063T3 (da) | 2003-12-22 |
EP0527063A1 (fr) | 1993-02-10 |
WO1992022644A1 (fr) | 1992-12-23 |
PT527063E (pt) | 2004-01-30 |
FR2677652A1 (fr) | 1992-12-18 |
CA2111238C (fr) | 2006-08-29 |
ATE248221T1 (de) | 2003-09-15 |
EP0527063B1 (fr) | 2003-08-27 |
ES2206444T3 (es) | 2004-05-16 |
CA2111238A1 (fr) | 1992-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06508515A (ja) | トランスジェニック哺乳類の乳汁中への所望なタンパク質の産生 | |
US4873316A (en) | Isolation of exogenous recombinant proteins from the milk of transgenic mammals | |
EP0247494B1 (en) | Method for evaluating the effect of a heterologous agent on an animal | |
US5750172A (en) | Transgenic non human mammal milk | |
US5565362A (en) | DNA sequences to target proteins to the mammary gland for efficient secretion | |
US5573933A (en) | Transgenic pigs | |
US20100305039A1 (en) | Production of collagen in the milk of transgenic mammals | |
JPH06506105A (ja) | 哺乳動物細胞における相同性組換え | |
JPH04501662A (ja) | 混合給送組換え酵母発酵 | |
CA2055500A1 (en) | Expression of polypeptides | |
EP0837931A1 (en) | Method for expression and isolation of biologically active molecules in urine | |
EP0451823A2 (de) | DNA-Konstrukte zur Expression von Proteinen in der Milchdrüse transgener Säugetiere | |
EP0771874B1 (en) | Transgenic protein production | |
US5965788A (en) | Transgenic non-human mammal comprising a rabbit WAP promoter | |
US6268545B1 (en) | Transgenic non-human mammal comprising a rabbit WAP promoter, uses thereof, and a DNA construct comprising the rabbit WAP promoter | |
EP0350052A2 (en) | Transgenic animals transformed with autonomously replicating sequence-containing plasmid | |
US7053262B2 (en) | Mammary gland tissue-specific expression system using β-casein promoter site of Korean native goat | |
US6018039A (en) | MC26 gene expression-regulatory region | |
CN101413003A (zh) | 在转基因哺乳动物的奶中生产外源蛋白的方法以及从其中纯化蛋白的方法 | |
Muglia | Regulation of albumin and alpha-fetoprotein gene expression | |
US20040266711A1 (en) | DNA sequences to target proteins to the mammary gland for efficient secretion | |
Bates | Protein production in the milk of genetically engineered animals | |
JPH02186931A (ja) | 遺伝子導入非ヒト動物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051017 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060509 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060628 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090707 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100707 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110707 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110707 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120707 Year of fee payment: 6 |
|
EXPY | Cancellation because of completion of term |